Imatinib Mesylate (Gleevec) in the Treatment of Systemic Sclerosis
Condition(s):Systemic SclerosisLast Updated:February 6, 2018Completed
Hide Studies Not Open or Pending
Condition(s):Systemic SclerosisLast Updated:February 6, 2018Completed
Condition(s):Scleroderma, Systemic; Fibrosis; SemaglutideLast Updated:March 5, 2024Recruiting
Condition(s):Scleroderma; SscLast Updated:October 26, 2017Completed
Condition(s):SclerodermaLast Updated:December 22, 2016Withdrawn
Condition(s):Diffuse Cutaneous Systemic SclerosisLast Updated:April 21, 2021Terminated
Condition(s):Scleroderma, SystemicLast Updated:March 13, 2019Completed
Condition(s):Scleroderma; Pulmonary HypertensionLast Updated:September 10, 2021Unknown status
Condition(s):Scleroderma, SystemicLast Updated:March 27, 2024Active, not recruiting
Condition(s):Systemic SclerosisLast Updated:June 30, 2008Completed
Condition(s):SclerodermaLast Updated:September 23, 2022Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.